With a genuinely groundbreaking research and development program and a strong IP portfolio BKG Pharma has created an extraordinary platform for future discovery and development of potential first-in-class small molecule antibiotics against MDR resistant infections. 

Based on QSAR analysis of the mode of action of existing drug candidates, novel compounds are continually being intelligently designed. By applying our method of intelligent exploration of the proprietary pool of compounds, we have already succeeded in discovering and developing new frontrunner compounds targeting selected MDR Gram-negative bacteria.